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Strategic Directions in Tissue Engineering
PETER C. JOHNSON, M.D.,1 ANTONIOS G. MIKOS, Ph.D.,2
JOHN P. FISHER, Ph.D.,3 and JOHN A. JANSEN, D.D.S., Ph.D.4
ABSTRACT
The field of tissue engineering is developing rapidly. Given its ultimate importance to clinical care, the time
is appropriate to assess the field’s strategic directions to optimize research and development activities. To
characterize strategic directions in tissue engineering, a distant but reachable clinical goal was proposed
and a worldwide body of 24 leaders in tissue engineering was queried systematically to determine the best
paths toward that goal. Using a modified Hoshin process, we identified 14 critical activity categories and
then stratified them by their immediate priority for the field. The result of the analysis illustrates a highly
interdependent set of activities that are dominated by the need for an understanding of angiogenesis, stem
cell science, and the utilization of molecular biology and systems biology tools to enable a deeper com-
prehension of tissue development and control.
INTRODUCTION
THE FIELD OF TISSUE ENGINEERING IS DIVERSE in its meth-ods and clinical targets and holds great promise for
improved patient care. It has matured to the point that its
activities can be reasonably well categorized, providing
the opportunity for a strategic assessment that is able to
guide researchers, funders, policy makers, regulators, and
technology developers. We undertook such an analysis with
the participation of the international editorial board of the
journal. Our hope was to obtain a strategic perspective on
the field from the point of view of those who are actively
developing its technologies around the world. In particular,
we concentrated on three topics:
1. Determining the critical activity foci for the field that
will enable it to progress
2. Characterizing the degree to which we have made
progress in these areas
3. Determining the linkages between activities and
stratify them on the basis of their predominance as
influencers of one another while taking into consider-
ation previous progress
In this way, we intended to provide ourselves as editors
with direction regarding the most critical issues facing the
field. In addition, we wanted to present the community with
the experienced perspective that our worldwide editorial
board has provided with respect to these issues.
To achieve this, a modified Hoshin* facilitation tech-
nique was used that uniquely enabled asynchronous inter-
national participation to complete the assessment. Members
of the editorial board were asked to identify critical steps
that would be needed to achieve the following goal: ‘‘The
field of tissue engineering will exhibit broad clinical suc-
cess by the year 2021.’’
Based upon their responses, a list of strategically im-
portant concepts was identified and prioritized on basis of
their immediate importance to the field. The data obtained
(listed in Appendix A) provide a focus for research and
development activities in the field that may assist in the
*Hoshin method—also known as the Hoshin Kanri method that means
‘‘sharp pointed metal’’ like the needle of a compass—is a strategic plan-
ning methodology that defines a mission, and then identifies and prioritizes
the tasks needed to achieve the mission.
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enhancement of research and development efficiency and
financing.
MATERIALS AND METHODS
Participants in the assessment
Twenty-four members of the editorial board of the
journal Tissue Engineering participated in this assessment.
(They are listed in the ‘‘Acknowledgments’’ section.)
Modified Hoshin method
The Hoshin facilitation process is a well-established stra-
tegic planning technique. It is designed to support group
strategic planning processes through the identification of a
common goal followed by delineation and prioritization of
the steps needed to achieve the goal. It is especially effective
in disparate groups, as it is designed to maximize the sharing
of ideas through active group participation. Although the
Hoshin process is normally run with a group working to-
gether at one location in real time, the nature of our partici-
pant community did not allow this. In thismodified approach,
one set of participants (the editorial board members) was
guided asynchronously through one part of the process while
the four editors-in-chief acted synchronously in the assess-
ment of the ideas provided by the editorial board.
The steps of the modified Hoshin process were as follows:
1. Mission creation: The mission (see above) was se-
lected and communicated electronically to the edito-
rial board. When the ideas were collected in late
2006, the goal was 15 years distant. This duration was
felt to credibly estimate the time needed for the field
to express significant clinical development potential.
2. Idea generation: The editorial board members were
asked to provide up to 10 critical ideas or steps that
would need to occur for the mission to be successful.
Twenty-four editorial board members representing
Asia, Africa, Europe, and North America participated in
the response.
3. Electronic idea collection: The ideas (145) were
collected from the editorial board members by e-mail.
4. Clustering of related ideas: Once all ideas were col-
lected, they were sorted on the basis of their similarity
into 14 distinct groups of ideas (see Appendix A).
5. Naming of clusters as concepts: The clustered idea
groups were provided an overarching name that en-
compassed the content of its collective ideas. These
clusters, known as ‘‘concepts,’’ are, in essence, ac-
tivity foci for the field.
6. Comparison of concepts to determine raw dominance:
Using standard Hoshin approaches, the concepts were
placed in a circle on paper and compared to one another
in sequential fashion until all pairwise comparisons
were completed. In each instance, the question was
asked: ‘‘Is there a relationship between these concepts?’’
If so, a line was drawn between the concepts and a
unidirectional arrow was assigned leading from the
dominant concept to the one that was dominated. Once
complete, the number of relationships (R) and the num-
ber of ‘‘out’’ or ‘‘dominant’’ arrows (O) were counted.
This process was performed by the editors-in-chief.
7. Assessment of progress to date: Each editor-in-chief
assigned a level of progress achieved thus far to each
concept. A scale of 1¼ no progress to 10¼ complete
progress was assigned. The mean progress level (P)
assigned by the four editors was used as the concept
progress designation for each concept.
8. Determination of normalized concept dominance: To
determine the most important concepts for immediate
focus, the dominance (O) of each concept was divided
by its level of present progress (P) and the divisor
O/P was obtained for each. On the basis of this figure,
concepts were sorted from most to least dominant.
RESULTS
Distillation of concepts from raw ideas
The 145 raw ideas provided by members of the editorial
board were grouped into concept categories on the basis of
their relatedness. Fourteen concepts were derived in this
way, as shown in Table 1. The similar ideas that led to each
concept classification are shown in the table, and the full text
of these ideas is provided in Appendix A.
Raw Hoshin data
Table 2 presents the raw data from the Hoshin analysis,
including the number of outgoing (dominant) arrows (O),
the total number of relationships of each concept with the
others (R), the mean estimated progress in the field thus far
(P), and the dividend of O/P, the dominance of the concept
TABLE 1. CONCEPTS AND NUMBERS
OF RAW IDEAS SUPPORTING THEM
Clinical understanding/interaction 21
Manufacturing/scale-up 19
Cell sourcing and cell/tissue characterization 15
Molecular biology/systems biology 15
Multilevel funding 12
Stem cell science 11
Pharmacoeconomic/commercial pathway 9
Enhanced biomaterial functionality 8
Standardized models 8
Regulatory transparency 7
Multidisciplinary understanding/cooperation 6
Immunologic understanding and control 5
Expectation management/communication 5
Angiogenic control 4
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normalized to present progress. The mean number of dom-
inant relationships per category was 6.1 3.8. The mean
number of relationships each concept had (out of a possible
13) was 12.1 1.0. The mean level of progress in the
field per concept was 4.3 0.9 out of a possible 10.
Concept relationship strength
As shown in Table 3, when sorted on the basis of rela-
tionship strength per category, the scattering of data is very
small, indicating an intense interrelatedness of critical con-
cepts in the field.
Raw dominance of concepts over one another
In Table 4, the concepts are depicted in the order of de-
creasing strength over one another. This listing represents
the raw importance of the concepts to the field without
taking into consideration progress to this point.
Concept progress thus far
Table 5 shows the estimated progress achieved thus far
(1¼ none; 10¼ complete) for each concept.
Normalized concept dominance (i.e., when
progress has been taken into consideration)
Table 6 illustrates the final dominance profile of the
concept areas once present levels of progress have been
taken into consideration. This is the sorted order of the
most critical concepts that require pursuit at this time.
TABLE 2. RAW HOSHIN DATA
Mean
O R Mean P O/P
Clinical understanding/interaction 10 13 4.5 2.2
Manufacturing/scale-up 4 11 3.5 1.1
Cell sourcing and cell/tissue characterization 10 12 3.8 2.7
Molecular biology/systems biology 11 11 4.0 2.8
Multilevel funding 0 13 4.8 0.0
Stem cell science 12 13 3.8 3.2
Pharmacoeconomic/commercial pathway 1 12 3.8 0.3
Enhanced biomaterial functionality 4 13 4.8 0.8
Standardized models 5 11 4.8 1.1
Regulatory transparency 5 13 4.5 1.1
Multidisciplinary understanding/cooperation 5 13 6.5 0.8
Immunologic understanding and control 7 12 3.5 2.0
Expectation management/communication 2 10 5.5 0.4
Angiogenic control 9 13 2.8 3.3
Mean 6.1 12.1 4.3 1.5
SD 3.8 1.0 0.9 1.1
TABLE 3. CONCEPTS SORTED AS A FUNCTION
OF RELATIONSHIP STRENGTH
Clinical understanding/interaction 13
Multilevel funding 13
Stem cell science 13
Enhanced biomaterial functionality 13
Regulatory transparency 13
Multidisciplinary understanding/cooperation 13
Angiogenic control 13
Cell sourcing and cell/tissue characterization 12
Pharmacoeconomic/commercial pathway 12
Immunologic understanding and control 12
Manufacturing/scale-up 11
Molecular biology/systems biology 11
Standardized models 11
Expectation management/communication 10
TABLE 4. CONCEPTS SORTED BY RAW DOMINANCE
Stem cell science 12
Molecular biology/systems biology 11
Clinical understanding/interaction 10
Cell sourcing and cell/tissue characterization 10
Angiogenic control 9
Immunologic understanding and control 7
Standardized models 5
Regulatory transparency 5
Multidisciplinary understanding/cooperation 5
Manufacturing/scale-up 4
Enhanced biomaterial functionality 4
Expectation management/communication 2
Pharmacoeconomic/commercial pathway 1
Multilevel funding 0
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Interconcept relationships
Table 7 reflects the actual relationships between con-
cepts. For each concept (lettered on the left), the group of
other concepts it dominates is shown on the right.
DISCUSSION
A check on the strategic direction of a field as diverse as
tissue engineering by its practitioners is periodically war-
ranted, if only to help focus our collective international
strengths. We originally performed this analysis to iden-
tify key focus areas for invited reviews and editorials for
the journal Tissue Engineering. However, as its process
unfolded, it became clear that since the analysis incorpo-
rated the thoughts of many of the world’s leaders in tissue
engineering, it might have a broader role in guiding the di-
rection of development of the field.
Since tissue engineering is ultimately focused on the
improvement of the care of patients, we chose a relevant
goal—the clinical success of the field by 2021—and then
culled the opinions of 24 key international leaders to deter-
mine the critical steps en route to this goal. They indepen-
dently created and submitted their responses, providing
a thoughtful snapshot of international opinion regarding
strategic directions in the field. Using the Hoshin analysis
methodology, these contributions were grouped by similar-
ity, classified into concepts, and the concepts were then
compared by the editors-in-chief of Tissue Engineering
Parts A, B, and C to determine their relative priority in
support of progress in the field. The Hoshin process has the
unique capacity to identify interrelationships between im-
portant strategic activity subsets. In this case, its applica-
tion led to a deeper understanding of what constitute the
most dominant directions in the field. Because of the way
that concept areas are linked together, a focus on the most
dominant concepts inevitably should lead to all concepts, in
turn.
An important step in this analysis is the assignment of
present progress in the field. While this is a subjective as-
sessment, it has proven itself to be a helpful tool in Hoshin
analyses since it allows very dominant ideas to be normal-
ized by the degree to which previous progress has been
made. Periodic progress reassessment and analysis of the
effect on concept dominance will be important in the years
ahead, to restructure priorities for the attention of funding
agencies and the like.
In the process of performing the analysis, we learned
several things. While some concept areas received attention
from many of the responding board members, the number of
ideas a concept area received did not correlate with its ulti-
mate strategic importance. This suggests that highly strate-
gic issues often may not lie at the forefront of our day-to-day
conception of the most important foci in the field, making
such analyses more important to undertake. For example, the
strategically most important category, angiogenic control,
was supported by only four contributed ideas. However, its
dominance over nine other concepts and its low level of
present progress propelled it to the top of the list of strategic
concepts. Clearly, mastering the control of angiogenesis
will be at the heart of any attempts to grow larger tissue-
engineered constructs than have thus far been achievable.
This will apply whether such growth occurs in vitro or within
the body as a response to cell and/or scaffold implantation.
Stem cell science is the second most strategic concept,
dominating 12 other concepts. It may well be that the un-
derstanding and control of stem cell development will en-
able us to short circuit some of the tissue engineering
methods used heretofore—perhaps allowing the concurrent
growth of vascular systems with parenchymal tissues.
To understand and control stem cell behavior, we need to
be able to measure cellular responses at the molecular level
TABLE 5. CONCEPTS SORTED AS A FUNCTION
OF PROGRESS ACHIEVED THUS FAR
P
Multidisciplinary understanding/cooperation 6.5
Expectation management/communication 5.5
Multilevel funding 4.8
Enhanced biomaterial functionality 4.8
Standardized models 4.8
Clinical understanding/interaction 4.5
Regulatory transparency 4.5
Molecular biology/systems biology 4.0
Cell sourcing and cell/tissue characterization 3.8
Stem cell science 3.8
Pharmacoeconomic/commercial pathway 3.8
Manufacturing/scale-up 3.5
Immunologic understanding and control 3.5
Angiogenic control 2.8
TABLE 6. NORMALIZED CONCEPT DOMINANCE
(I.E., TAKING PRESENT PROGRESS INTO CONSIDERATION)
O/P
Angiogenic control 3.3
Stem cell science 3.2
Molecular biology/systems biology 2.8
Cell sourcing and cell/tissue characterization 2.7
Clinical understanding/interaction 2.2
Immunologic understanding and control 2.0
Manufacturing/scale-up 1.1
Regulatory transparency 1.1
Standardized models 1.1
Enhanced biomaterial functionality 0.8
Multidisciplinary understanding/cooperation 0.8
Expectation management/communication 0.4
Pharmacoeconomic/commercial pathway 0.3
Multilevel funding 0.0
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and thereby characterize cause-and-effect relationships. Re-
cent advances in molecular biology and systems biology
enable us to do this, making this concept area highly strategic
for future developments throughout the field. The continuum
of measurable cell characteristics (genome sequence, gene
expression arrays, and proteomic and metabolomic patterns)
can now be combined with digital automated histology in-
formation to provide a systems biology view of tissue de-
velopment. Information systems are now capable of properly
aggregating and analyzing such information, enabling the
identification of biomarkers of development that can be used
for guidance in engineered tissue development.
While standardized cell sourcing for tissue engineering
applications remains a problem in flux, the characterization
of cells and tissues, as stated above, will make whatever cells
that are sourced be far better understood in their ultimate
behaviors. Cell sourcing remains a critically important focus
area for the field.
At this point in the analysis, the concept that was sup-
ported by the largest number of ideas, clinical understanding
and interaction, finds its strategic position. Clearly, if the
field is oriented toward clinical applications, close engage-
ment of the clinical community is important. This is not only
valuable for the establishment of engineered tissue design
criteria but also to enhance the potential for the ultimate
acceptance of such therapies into clinical practice at large.
Fortunately, significant progress has been made in the
weaving of scientific and engineering groups together with
clinicians for the mutual development of the field.
Though often overlooked, immunologic understanding
and control will be an important hurdle for the field in the
coming years. Depending upon the sources of standardized
cells (autologous vs. allogeneic) and on the antigen pre-
sentation of cells derived from stem cells, immunologic
understanding will prove to be of increasing importance.
The development of a discipline known as the Immunology
of Engineered Tissue would be timely, so that the need for
immunologic response controls in the face of implanted
engineered tissues can be understood.
Though perhaps premature in some cases, the ultimate
need for manufacturing/scale-up will be prevalent through-
out the field. It is placed high on the list of strategic concepts
for this reason. Issues in manufacturing and scale-up go hand
in hand with those of cell sourcing and characterization.
Several groups around the world are formally engaged in this
discipline at this time.
Regulatory transparency is next on the strategic concept
list. While a great deal of effort has been expended by United
States and international regulatory authorities in preparing
to understand and regulate engineered tissues, clear pathways
through the regulatory process have not yet been completely
defined. It is supposed that the greater capacity for cell and
tissue characterization using molecular biology and systems
biology tools will provide assurances regarding cell behav-
ior and fate that will enable regulatory authorities to assess
the appropriate data needed to transparently regulate tissue-
engineered products.
Regulatory authorities will benefit from the development
of acceptable standardized models of engineered tissue im-
plantation. It is early in the process of developing such
models but they will be critically needed as the next wave of
engineered tissue technologies reaches preclinical experi-
mentation milestones.
While biomaterial scaffolds have been a mainstay in the
field for years, the strategic importance of enhanced bio-
material functionality depends quite heavily on what we
learn about cells and tissues using the new characterization
methodologies. While functional biomaterials will be of
great importance as delivery vehicles for engineered tissue
technologies, their design will grow from the known natural
needs and responses of functional tissues themselves.
Fortunately, substantial progress has been made in the con-
cept area of multidisciplinary understanding and cooperation.
Indeed, this is something of a birthright for the field of tissue
engineering, which put so much effort into this focal area in
its early years, not only within research groups but also
through the many regional initiatives that have dotted the
landscape of the field. Collaboration and information sharing
TABLE 7. THE DOMINANT RELATIONSHIPS BETWEEN CONCEPTS
A Clinical understanding/interaction B, E, G, H, I, J, K, L, M, N
B Manufacturing/scale-up E, G, H, M
C Cell sourcing and cell/tissue characterization A, B, E, G, H, I, J, K, L, N
D Molecular biology/systems biology A, B, C, E, F, H, I, J, K, L, N
E Multilevel funding
F Stem cell science A, B, C, E, G, H, I, J, K, L, M, N
G Pharmacoeconomic/commercial pathway E
H Enhanced biomaterial functionality E, G, K, M
I Standardized models E, G, H, J, K
J Regulatory transparency B, E, G, H, M
K Multidisciplinary understanding/cooperation B, E, G, J, M
L Immunologic understanding and control E, G, H, I, J, K, M
M Expectation management/communication E, G
N Angiogenic control B, E, G, H, I, J, K, L, M
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with an eye toward effective communication are among the
pillars of the field’s development.
Similarly, while the field initially perhaps touted its po-
tential with excessive alacrity, we seem to have matured into
a solid appreciation of the importance of expectation man-
agement and communication so that future advances can be
received by clinicians and the public as having the real value
stated at the time.
Commercial processes for the development of tissue-
engineered products are known to be critical for these prod-
ucts to reach the bedside. Fortunately, the analysis shows
that knowledge of how these processes work is generally
extant, making pharmacoeconomic/commercial pathway
considerations more generally resolvable and therefore of
less critical importance on the immediate strategic pathway.
This may change as nascent technologies ripen and com-
mercial pathway issues become rate limiting. This under-
scores the need for a periodic reassessment of strategic data.
Finally, while one might think reflexively that multilevel
funding is the key driver of the field, in fact it appears to be
the opposite. That is, funds are actually allocated and re-
leased at both research and commercialization levels on the
basis of the credibility of technology or its potential for
development. As a result, funding decisions are made on the
basis of successful progress in other strategic concept areas,
such as evidence of clinical and multidisciplinary interac-
tion, availability of tools for cell and tissue characterization,
harnessing of stem cell responses, and the like. While
funding is a chicken-and-egg situation, it is clear from the
beginnings of the field that substantial funding always fol-
lows tangible technology development.
When the analysis is viewed through the lens of progress
achieved in the field thus far, it is clear that a good job has
been done by bringing scientific, engineering, and clinical
disciplines together, by enabling the generation of a sub-
stantial stream of funding, by moving forward the devel-
opment of biomaterials, and by the creation of a reasonable
regulatory transparency. However, a great deal of work has
yet to be done before angiogenic systems can be created for
advanced tissue growth, stem cell and immunologic be-
havior is tied together meaningfully, and all of our scale-up
needs are reached. This is why the latter rate highly in the
priority of strategic concept areas.
Fortunately, aswe progress, comfort can be taken in the fact
that developments in any of these areas are likely to positively
impact the whole of the field. Remarkably, when the number
of relationships was measured per concept area, the mean
number of relationships per concept area (out of a possible 13)
was 12.1, six of these being dominant relationships.
Recently, a strategic assessment of the field from the
MATES group of Federal agencies was released.{ The
results of this multiyear project provided the following
critical priorities for the field:
 ‘‘Understanding the Cellular Machinery
 Identifying, Validating Biomarkers and Assays
 Advancing Imaging Technologies
 Defining Cell/Environment Interactions
 Establishing Computational Modeling Systems
 Assembling and Maintaining Complex Tissue
 Improving Tissue Preservation and Storage
 Facilitating Effective Applications Development and
Commercialization’’
These were not prioritized but were listed in the order of
the pathway from research to commercialization.
The report pointed out four overarching goals for the
field:
1. ‘‘Understanding and controlling the cellular response:
A fundamental challenge is to understand how cells—
the building blocks of tissues—receive and respond to
information from their local environment in estab-
lishing and maintaining tissues.
2. Formulating biomaterial scaffolds and the tissue
matrix environment: The scaffolding that supports
cells and gives tissues their form is increasingly ap-
preciated as an important source of information
that drives cell fate determination. A deeper under-
standing of the biology underlying this relationship
will allow more effective tissue design and engi-
neering.
3. Developing enabling tools: Complex, multiparametric
inputs are required to assess the state of a tissue and the
cells within it. This information will be supplied by
improvements in high-throughput assays and instru-
mentation, imaging modalities, fabrication technolo-
gies, computational modeling, and bioinformatics.
Additionally, tissue preservation technologies and
bioreactors will facilitate the generation of tissues
on demand.
4. Promoting scale-up, translation, and commercializa-
tion: Demonstrating the feasibility of designing an
engineered tissue is not enough. Realizing the full
benefits tissue engineering science requires increased
reproducibility, robustness, and user-friendliness that
will enable the broad distribution of products.’’
In assessing worldwide opinion through our strategic
planning process, it has become clear that the MATES group
and the international community are thinking along similar
lines. This is reassuring and exciting. It is our expectation
that the progress assessment and prioritization provided by
the Hoshin methodology, along with the tactical approaches
suggested in the raw ideas (Appendix A), may add value
within the overarching themes presented in the MATES
report and also suggest some prioritization of funding sup-
port for the field.
{Advancing Tissue Science and Engineering: A Multi-Agency Strategic
Plan, U.S. Government Multi-Agency Tissue Engineering Science
(MATES) Interagency Working Group, National Science and Technology
Council, 2007. Web site: http://tissueengineering.gov/welcome-s.htm.
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As editors of the Tissue Engineering journal, we antici-
pate that this analysis will be of some benefit to those
planning their research, designing institutes and teaching
programs, and allocating funding for the future development
of the field.
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APPENDIX A: CONCEPTS AND THEIR
UNDERPINNING IDEAS
The following list contains all the concept headings and
the raw ideas they comprise. The ideas themselves provide
good tactical directions for the enhancement of the field.
They are listed here in unedited form to convey their initial
meaning.
Clinical Understanding/Interaction (21 ideas; 14.5%)
- Widespread buy-in by clinicians and healthcare pro-
viders (Market pull)
- Define by clinical epidemiology the area for needs for
tissue engineering
- Define on a public health level the needs and the cost
implications
- Consider that ‘‘engineering’’ requires a ‘‘design’’
- Clinical trials. There need to be more (Phase 1) human
trials of tissue-engineered constructs. This relates to the
importance of employing relevant animal models in
preclinical investigation.
- Close interactions between bioengineers and clinical
scientists
- Get support for clinical trials
- Identification of achievable clinical targets (can it be
done?)
- Focus research on clinically relevant issues (priority of
clinic over technology)
- Engaging the clinical stakeholders more specifically the
surgeons and trauma units
- Translation into the clinical arena for applied tissue
engineering
- Centralized facilities versus decentralized facilities
- Encourage research on influence of boundary condi-
tions on outcome of TE treatments (joint swelling,
hematoma formation, diabetes, etc.)
- Successful carefully constructed and quantitated clini-
cal trials associated with the successful creation of an
International network
- Long-term patient/product follow-up registers (exten-
sion of Phase IV clinical trials)
- Shift resources from animal studies into professionally
managed clinical trials, with validated outcome mea-
sures
- Demonstrate clear clinical success with a cell-based
treatment of a significant disease (diabetes, Parkin-
son’s, etc.)
- Development of strategies for clinical implementation
of new TE treatments by identifying suitable patient
(sub)populations
- Development of methodologies to translate measured
patient-specific parameters into patient-specific thera-
pies, i.e., there will not be silver-bullet, one therapy fits
all solutions
- Identification of products that meet a clinical need (do
not directly compete with products already on the
market, meeting that need)
- Translation of proof-of-concept technology into actual
clinical application and evaluation
- Build more complicated organs such as liver, kid-
ney, and heart to overcome the shortage of these
organs
Manufacturing/Scale-Up (19 ideas; 13.1%)
- Scaling up of the tissue engineering products to
the final dimensions necessary for the human pa-
tients
- Development of tissue regeneration acceleration tech-
nology
- Develop low-cost automated production of cell-based
products
- Development of efficient manufacturing processes
- Scalable, cost-effective production under GMP (Good
manufacturing practice)
- Develop closed bioreactor systems for standardized,
safe, and controlled manufacture of grafts
- Reduce the cost of growing cells at the industrial level to
encourage companies to build a central cell manufactur-
ing sites
- Development of reproducible tissue regeneration meth-
odology
- To be able to better store tissue-engineered products so
they can last longer
- Simplicity and off-the-shelf products for ubiquitous use
- Totally animal-free products with all components clearly
defined and consistent in quality
- Identify quality controls for the implant potency (e.g.,
predictive markers of cell function, not just viability
tests)
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- Develop low-cost automated production of cell-based
products
- Development ofworkable tissue preservation technology
- Sharing safety/toxicity international databases
- Consistent robust products which can be stored for long
periods and easily transported and implanted into pa-
tients
- To be able to better store tissue-engineered products so
they can last longer
- In vitro tissue engineering for in vivo implantation
- Scale-up and bioreactors
 Development of appropriate animal models and pre-
clinical evaluation criteria as indicators for clinical
investigations
 Coculture of two or multiple types of cells/tissue
 Functional vascularization for large tissue
 New biodegradable materials with fine-tuned degra-
dation and acceptable safety profiles for the devel-
opment of combination products
 Characterization criteria for in vivo implantation
 Mass transport and mechanical (shear) effect on tis-
sue development
 Cryopreservation of combination product
Cell Sourcing and Cell/Tissue Characterization
(15 ideas; 7.3%)
- Availability of distinct cell sources for tissue regener-
ation
- Cell and tissue characterization
- Adequate cell sourcing
- Cell characterization
- Better understanding the cellular, molecular & struc-
tural components of healthy tissues. This information
is needed to better build tissue engineering products.
- New imaging technology for postgrafting evaluation of
tissue engineering substitutes
- Cell and tissue imaging
- Cell and tissue tracking
- Development of high-throughput methods for testing
tissue function
- Development of universal donor cell lines
- Research studies including meaningful in vivo func-
tionality studies
- Identification of a consistent and plentiful cell source
- A more thorough understanding of the biology and
cell–cell interactions among different cell types
- Crystal ball
 Technologies to support cell therapies
 Human cell source, well characterized, standardized,
serum free
 Materials and delivery routes for enhanced cell re-
tention, coupling
- Challenges ahead
 Challenge 1: Human cell source
 Resident cells, stem cells, cell banks
 Cell culture without animal components
 Standardization of cell derivation & characteriza-
tion
Molecular Biology/Systems Biology (15 ideas; 7.3%)
- Thorough control of the human genome of the cells
involved
- Use of genomics and proteomic technologies to un-
derstand the structure/function relationship in en-
gineered tissues
- A significantly deeper understanding must be gained
about the biology/physiology of tissue regeneration at
the genomic and proteomic levels
- Create a table of proteins that every healthy and dis-
eased tissue (cells) secrete, i.e., create a profile. This
information is needed to better build tissue engineering
products
- Genetic profiling
- Development of regulatable gene delivery vectors to
allow for manipulation of tissue function and engi-
neering structure/function relationships
- Understanding cell differentiation in the context of
three-dimensional tissues
- Better insight in cell-signaling pathways and develop-
ment of new strategies for the usage of growth factors
(including siRNA)
- Control of the microenvironment, signaling environ-
ment, mechanical environment, biological environ-
ment
- Establish procedures and protocols that ensure that
stem cells and their progeny are well tolerated in al-
logeneic cell transplants
- Multiple growth factors and their roles to promote
complete regeneration of tissue structures
- Signal regulationwithin ECMs
- Improved technologies for enabling safe and predict-
able biomimetic delivery of signaling molecules
- Understanding differentiation routes of human adult
and/or human embryonic stem cells to one or more
lineages
- Cell programming and developmental biology: Strategy
for expansion of human embryonic stem cells under
defined conditions
 Understanding of critical components of native stem
cell niches
 Artificial stem cell niche with defined parameters
 Availability of new embryonic stem cell lines
 Continuous federal and private funding
 Corporate collaboration with academia
Multilevel Funding (12 ideas; 8.3%)
- More funding of tissue engineering especially for
projects with strong translational component
- Increased NIH funding for:
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 training graduates and post-docs to become the next-
generation tissue engineers
 maintaining or expanding the academic research in-
frastructures in which they will training, including
increased funding for R01s
- Sufficient capital investment from private and govern-
ment sources
- P.S. I have four more bullets:
 More money
 More money
 More money
 More money :-)
- Investment at the early–mid level (post SBIR) stage
- Investment at the early (SBIR level) stage
- Availability of substantial R&D financial support
- Early stage (R01) research being targeted at transla-
tional research with outcomes that can have impact
- NIH funding of translational research in tissue engi-
neering, including large animal studies and integrative
studies utilizing stem cells, biomaterials, and/or bio-
active factors in an in vivo environment
- Sufficient corporate or venture capital investment
- Appropriate funding from venture capital and angel
investors
- Investment both in more fundamental research and in
more translational/clinical research
Stem Cell Science (11 ideas; 7.6%)
- Understanding stem cell differentiation
- Develop strategies for endogenous regenerative thera-
pies, i.e., using endogenous stem cells instead of ex vivo
expanding cells
- Isolation, characterization of human adult stem cells
from different adult tissues
- Pragmatic system of ethical regulation with respect to
human embryonic stem cells and derived products
- Use of stem cells
- Stem cells (especially for allograft) for tissue regener-
ation
- Differentiation of stem cells (in vitro and in vivo)
- Robust, efficient, and predictable processes for ex-
panding stem cell populations, in vitro, to sufficient
numbers required for therapeutic delivery
- Increase fundamental knowledge of stem cell charac-
terization, selection, and differentiation
- Route of delivery of stem cells for tissue regeneration
- Stem cell programming
 Understanding of signaling controls of fate-
specification (tissue specific)
 Guided differentiation of embryonic stem cells and
adult stem cells
 Geneticmanipulation (stable transduction) of stem cells
 Topographical and biochemical cues controlling fate
specification
 Biodegradable scaffolds for in vivo implantation as
combination product with cells
 Maturation of stem cells or progenitor cells and in-
tegration in vivo
 Continuous federal and private funding
Pharmacoeconomic/Commercial Pathway
(9 ideas; 6.2%)
- Identification of products that meet a clinical need (do
not directly compete with products already on the
market, meeting that need)
- Understanding the complete product development
pathway for tissue engineering (not just the combina-
tion product FDA issue)
- Clear reimbursement guidelines
- Prove that TE solutions are more economical than
traditional techniques
- Products which demonstrate very clear benefits over
conventional products, i.e., a real step-change in pa-
tient therapy
- Analyze the commercial situation and do an appro-
priate market analysis to assure a long-term profit-
ability for the motivation of industry
- Successful cost/benefit analysis of Tissue Engineering
products WITH the input of tissue Engineering society
and regenerative medicine societies
- Established international markets and distribution net-
works
- Stable global industry with a good supply of skilled
labor and other resources including capital
Enhanced Biomaterial Functionality (8 ideas; 5.5%)
- Scaffolding technology
 Spatial and temporal control of biochemical cues
 Local presentation of growth factors (sustained re-
lease and surface clustered)
- Cell selective interface and coculture capability
 Biomimetic functionalization of scaffold
 Stimuli-sensitive and injectable hydrogels
 Scaffold processing and relevant nanotechnology
- New generation of scaffolds
- Biomaterial characterization
- Proper design of scaffolds with ‘‘smart properties’’
- Cell/gene and material interactions
- Engineering cell–cell interactions in 3D to mimic na-
tive tissues
- Inductive bone implants with the addition of either
growth factors or expanded cells
- Challenge: Enabling technologies
 Cell instructive environments (scaffolds, bioreactors),
functional imaging
 Vascularization (functional perfusion; capillary bed
for oxygen supply)
 Rigorous animal models, imaging
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Standardized Models (8 ideas; 5.5%)
- Standardized in vivo models
- Meaningful animal models
- Tools for more efficient discovery, e.g., how to effi-
ciently (cost and time) search massive design spaces
(in vitro and in vivo), and how to more efficiently
utilize animal models
- Development/utilization of animal models that repre-
sent clinical problems
- Development of appropriate animal models (other
than mice or rats) for testing of tissue-engineered
products
- In vivo test in large animals using a clinically relevant
model
- Controllable models for biological and medical re-
search
 High-throughput screening, biomimetic context
 Tissue models of development, disease
- Implementation of animal models that relate directly to
specific compelling applications of tissue engineering in
the clinic. For example, many in vivo studies address
strategies for the engineering of a selected tissue, but
few investigate the tissue-engineered constructs in a
model that closely reflects a specific clinical application,
with the current ‘‘gold standards’’ for treating the dis-
order as controls.
Regulatory Transparency (7 ideas; 4.8%)
- Clear regulatory pathways with regulation achievable
in a timely and cost-effective manner
- Regulatory expertise
- Clarify FDA regulatory guidelines for tissue engineer-
ing products
- Clarity from the FDA with respect to regulation of
tissue regeneration products
- Obtain international consensus on the regulation of
cell-based products
- Continuous dialogue with specialists within registration
authorities as ‘‘partners’’ rather than judges
- Establish softer trial rules for ‘‘non commercial’’ clin-
ical trials
Multidisciplinary Understanding/Cooperation
(6 ideas; 4.1%)
- Encourage the formation of consortia that work on a
specific topic (low back pain, joint trauma, etc.)
- Bring different groups into one specific area vs. one
group mastering all fields
- Improve interdisciplinary networking (clinical medi-
cine, biology/embryology, material sciences, bio-
chemistry)
- Improvement of collaboration between research and
industry
- Invest in multidisciplinarity of the field by bringing
researchers from different fields better together
- Challenge: Cross-disciplinary approach
 Biology, engineering, medicine, industry
 Computational biology (data mining, modeling of
regulatory pathways)
 Joint conferences, workshops
 Funding mechanisms
Immunologic Understanding and Control
(5 ideas; 3.5%)
- Develop conditions for xeno-free defined expansion of
ES cells with stable karyotype
- Modulation of the immunologic responses to allogenic
cells
- Establish technologies to overcome the rejection of
organs and tissue-engineered products
- Establish procedures and protocols that ensure that
stem cells and their progeny are well tolerated in al-
logeneic cell transplants
- Recruit adverse tissue reactivity in a positive direc-
tion
Expectation Management/Communication
(5 ideas; 3.5%)
- Let’s be objective about what we promise
- Not to repeat the mistakes of gene therapy (promise too
much)
- Patient demand based on real expectations rather than
media hype (Market pull)
- Scientifically honest communication of results vs. me-
dia-driven popularistic claims
- Broaden the scope of tissue engineering to include
in vivo applications of biomaterials, homing of cells by
biomaterials, cell-interactive biomedical devices, for
example
Angiogenic Control (4 ideas; 2.8%)
- Control of angiogenesis
- Achieve histointegration
- Revascularization within ECMs (angiogenesis/arter-
iogenesis, in vitro and in vivo)
- Achieve rapid vascularization of TE constructs
Additional References:
Hoshin methodology
The Hoshin method used in the preparation of this report
is a custom-modified form. However, good descriptions of
the classic Hoshin method, along with tools for its execu-
tion, can be found at this Web site: http://www.tqe.com/
hoshhdbk.html.
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Of note is that the Hoshin process was successfully used
in the planning retreat (1996) to support the development of
the first formal NIH request for proposals in tissue engi-
neering in 1997:
RFA: HL-97-005: TISSUE ENGINEERING, BIOMI-
METICS, AND MEDICAL IMPLANT SCIENCE, NIH
GUIDE, Volume 26, Number 13, April 25, 1997.
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